Crux Biomedical The company is developing a retrievable Inferior Vena Cava (IVC) Filter that promises to be a great improvement over existing modes of treatment. The device has been successfully tested in animal studies in 2006 and was recently implanted in humans. Crux is currently working with the FDA to design and implement large-scale human clinical trials. The clinical trials should begin in March 2007.


Date Type Amount Investors Valuation
11/30/07 Series B 2.25M Scott Cook, Alloy Ventures, Growth Capital, Hercules Technology Growth Capital Unknown